Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung04 first-line trastuzumab deruxtecan in HER2-mutant advanced NSCLC
CTR20213132Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jun 2022; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20213132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213132.